SLC31A1 and neoplasm: In clinical setting of platinum-based chemotherapy for NSCLC, patients with undetectable SLC31A1 in tumors have reduced platinum concentration, decreased tumor response and shorter survival 4, 6, while ABCG2 expression in biopsy specimen predicts shorter survival 7, 8.